Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273817 | 0.86 | CMA1 (0.37) | NOX4HSD11B1CMA1PTGS1PTGS2 | |
| SCHEMBL40666 | 0.82 | ADRB1 (0.51) | CMA1 | |
| SCHEMBL15077177 | 0.82 | DGAT1 (0.43) | HSD11B1EIF2AK2 | |
| SCHEMBL305860 | 0.81 | ALDH1A1 (0.55) | EIF2AK2 | |
| SCHEMBL13737111 | 0.80 | ALDH1A1 (0.56) | PTGS1PTGS2 | |
| SCHEMBL27886229 | 0.79 | DDB1 (0.47) | CMA1EIF2AK2 | |
| SCHEMBL8195822 | 0.78 | SLC6A2 (0.46) | NOX4HSD11B1TRPV1CA12CA2 | |
| SCHEMBL20956958 | 0.78 | LIPE (0.49) | OPRL1 | |
| SCHEMBL8581320 | 0.78 | LIPE (0.46) | — | |
| SCHEMBL2960834 | 0.77 | ADRB2 (0.48) | EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20140221374-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2702052-A1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-2686317-A2 | RAF KINASE INHIBITORS | Selexagen Therapeutics, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8334313-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012125981-A2 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| EP-1542667-B1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-7902241-B2 | 3-[3-(4-ISOPROPYLPHENYL)-2,5-DIOXO-IMIDAZOLIDIN-1-YL]- or 2-OXO-2,3-DIHYDROIMIDAZOL-1-YL]BENZOIC ACID; modulating premature translation termination and nonsense-mediated mRNA decay; gene therapy; cystic fibrosis or Duchenne muscular dystrophy; cancer, autoimmune disease, blood disease, diabetes | PTC THERAPEUTICS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20060223872-A1 | Insecticidal phthalamide derivatives | BAYER CROPSCIENCE AG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| CN-1759105-A | Phthalamide derivatives having insecticidal activity | BAYER CROPSCIENCE AG (DE) | 2006-04-12 | — | — | CN | disclosed |
| EP-1542667-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-5990139-A | 2,5-DIOXO-4-(PYRIDYL OR PHENYL-(N-HETEROCYCLE(C4N,C3N2))-ALKYLENOXY-(1,4-PHENYLENE) -)THIADIAZOLIDINES; ANTIDIABETIC AND -LIPEMIC AGENTS; SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1999-11-23 | — | — | US | disclosed |
| US-5792780-A | FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0657449-B1 | Azole compounds, their production and use as antifungal agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-04-08 | — | — | EP | disclosed |
| US-5545652-A | Triazole and imidazole compounds and their use as antifungal therapeutic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-13 | — | — | US | disclosed |
| EP-0657449-A1 | Azole compounds, their production and use as antifungal agents | Takeda Chemical Industries, Ltd. (JP) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, VHL, URB2 | NOX4 4107/4885HSD11B1 2144/4885CMA1 3088/4885 |
| US-20140221374-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | NOX4 2195/4885HSD11B1 2337/4885CMA1 3072/4885 |
| US-20060223872-A1 | Insecticidal phthalamide derivatives | CRYAA, PRXL2A, H1-2 | NOX4 1351/4885HSD11B1 3703/4885CMA1 3716/4885 |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | NOX4 4107/4885HSD11B1 2144/4885CMA1 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.